Publications by authors named "P Bindi"

Objective: We aimed to investigate the remission rate and disease duration in idiopathic or post-cardiac injury pericarditis and risk factors for disease duration and anti-interleukin-1 (IL-1) agent discontinuation.

Methods: This was a multicenter, longitudinal, observational study including 370 patients (51.4% female).

View Article and Find Full Text PDF
Article Synopsis
  • COVID-19 poses significant risks for patients with end-stage renal disease (ESRD), with a study showing 5.5% of 2336 dialysis patients diagnosed with the virus.
  • Among those followed for over 28 days, 37% experienced severe outcomes and 28% died, with oxygen therapy and decreased lymphocyte counts identified as major risk factors.
  • The study noted that chronic use of angiotensin II receptor blockers (ARBs) may protect against mortality, while treatments like azithromycin and hydroxychloroquine showed no benefit for patients with COVID-19.
View Article and Find Full Text PDF

Immunotactoid glomerulopathy is a rare disease defined by glomerular microtubular immunoglobulin deposits. Since management and long-term outcomes remain poorly described, we retrospectively analyzed results of 27 adults from 21 departments of nephrology in France accrued over 19 years. Inclusion criteria were presence of glomerular Congo red-negative monotypic immunoglobulin deposits with ultrastructural microtubular organization, without evidence for cryoglobulinemic glomerulonephritis.

View Article and Find Full Text PDF

Several cases of sarcoidosis with pulmonary, neurological or ophthalmological involvement occurring during a treatment by anti-TNFα have been reported in the literature. We report a 66-year-old man who presented with renal failure and hypercalcaemia, associated with fatigue, shortness of breath and dry cough. He was receiving infliximab since 2004 for psoriatic arthritis.

View Article and Find Full Text PDF

Erdheim-Chester disease (ECD) is a rare form of non-Langerhans histiocytosis, with noncodified therapeutic management and high mortality. No treatment has yet been shown to improve survival in these patients. We conducted a multicenter prospective observational cohort study to assess whether extraskeletal manifestations and interferon-α treatment would influence survival in a large cohort of ECD patients.

View Article and Find Full Text PDF